<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362478</url>
  </required_header>
  <id_info>
    <org_study_id>99083</org_study_id>
    <nct_id>NCT01362478</nct_id>
  </id_info>
  <brief_title>Gene Promoter DNA Methylations and Their Relationships With Endophenotypes in Patients With Schizophrenia</brief_title>
  <official_title>Gene Promoter DNA Methylations and Their Relationships With Endophenotypes in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a disabling mental disease affecting about 1% of the worldwide population.&#xD;
      There is an overall heritability estimate of 68% for the underlying liability to&#xD;
      schizophrenia. Molecular epigenetic studies can overcome the complexities of traditional&#xD;
      genetic studies and provide a new framework for the search of etiological factors in&#xD;
      schizophrenia.&#xD;
&#xD;
      DNA methylation provides an example of an epigenetic process that affects gene expression.&#xD;
      Several postmortem experiments have found that increased DNA methylation at the glutamic acid&#xD;
      decarboxylase (GAD67) and reelin promoter, and hypomethylation of membrane-bound&#xD;
      catechol-O-methyltransferase (MB-COMT) promoter gene in prefrontal cortex of schizophrenia&#xD;
      patients.&#xD;
&#xD;
      Because it is impossible to obtain brain tissue from schizophrenia patients clinically, the&#xD;
      peripheral blood mononuclear cell (PBMC) can partly represent the brain gene expression. It&#xD;
      has been reported to use PBMC as biomarkers for epigenetic abnormalities, such as histone&#xD;
      acetylation and methylation, in schizophrenia. To the investigators best knowledge, gene&#xD;
      promoter DNA methylation abnormalities in schizophrenia have been limited to postmortem&#xD;
      study. It warrants to studying the DNA methylation using schizophrenia's PBMC.&#xD;
&#xD;
      Recently, endophenotype strategy has emerged as an important tool in understanding the&#xD;
      genetic architecture of schizophrenia. Some cognitive functions, such as attention and&#xD;
      working memory (WM), have been used as candidate endophenotypes for genetic studies in&#xD;
      schizophrenia. Synchronized GABA neurotransmission in the dorsolateral prefrontal cortex is&#xD;
      required for adequate attention and working memory, suggesting that impairments in&#xD;
      GABA-mediated inhibition in the prefrontal cortex could contribute to the endophenotype&#xD;
      presentations in schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be approved by Institutional Review Board of participated institutions before&#xD;
      recruiting patients. We will recruit 60 patients with schizophrenia and 60 healthy control&#xD;
      subjects after explaining the study goal and getting the informed consents.&#xD;
&#xD;
      We will evaluate the performance of continuous performance test (CPT) and working memory&#xD;
      subset in Chinese version of WAIS-III in both case and control subjects. We will assay&#xD;
      reelin, GAD, and MB-COMT gene promoter DNA methylation using methylation specific PCR (MSP)&#xD;
      and quantify these gene expression using quantitative reverse transcription polymerase chain&#xD;
      reaction (qRT-PCR).&#xD;
&#xD;
      Patients will be followed in one year and receive the same evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gene promoter DNA methylations&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        schizophrenia patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Case&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  age 20-65 year-old&#xD;
&#xD;
          -  fulfill DSM-IV criteria of schizophrenia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who are pregnant or have significant medical conditions&#xD;
&#xD;
          -  unstable psychiatric features (e.g. suicidal), too agitation&#xD;
&#xD;
          -  a history of substance abuse or drug addiction within the previous 6 months, with the&#xD;
             exception of nicotine dependence.&#xD;
&#xD;
        Control&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  20-65 year-old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  to have major psychiatric disorder, such as schizophrenia, mood disorders, and&#xD;
             substance use disorders, except nicotine&#xD;
&#xD;
          -  to have family history of schizophrenia, mood disorders, and substance use disorders&#xD;
&#xD;
          -  to have serious medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Hsin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Medical University WanFang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun-Hsin Chen, MD</last_name>
    <phone>886-2-29307930</phone>
    <phone_ext>53961</phone_ext>
    <email>chunhsin57@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>WanFang Hospital, Taipei Medical University</name>
      <address>
        <city>Taipei</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Hsin Chen, MD</last_name>
      <phone>886-2-29307930</phone>
      <phone_ext>53961</phone_ext>
      <email>chunhsin57@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chun-Hsin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University - WanFang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chun-Hsin Chen</last_name>
      <phone>886-2-29307930</phone>
      <phone_ext>53961</phone_ext>
      <email>chunhsin57@yahoo.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>May 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University WanFang Hospital</investigator_affiliation>
    <investigator_full_name>Chun-Hsin Chen</investigator_full_name>
    <investigator_title>Staff, Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>gene promoter</keyword>
  <keyword>methylation</keyword>
  <keyword>endophenotype</keyword>
  <keyword>epigenetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

